Ascent signs $200 million licensing option with Novartis
This article was originally published in Scrip
Executive Summary
Ascent Therapeutics has agreed a $200 million licensing option with a Novartis fund to discover and develop Pepducin drug candidates. Ascent is also eligible for royalties for developing compounds against an undisclosed G-protein coupled receptor (GPCR) target.